Customer Validation
- •Neurochem Res. 2017 Apr 22.
| Description |
Minocycline is a tetracycline antibiotic with neuroprotective, antiapoptotic, anti-inflammatory and antimicrobial effects. IC50 Value: N/A Target: Antibacterial Minocycline acts as a matrix metalloproteinase (MMP) inhibitor; attenuates disease severity in mouse models of multiple sclerosis. Minocycline also inhibit the enzymatic activity of poly(ADP-ribose) polymerase-1 (PARP-1) and angiogenesis. In addition, Minocycline is suggested to down-regulate CD40L on T cells and inhibit the replication of SIV and HIV. Orally active and brain penetrant. |
|---|---|
| Clinical Trial |
View MoreCollapse
|
| References |
|
| Preparing Stock Solutions |
Please refer to the solubility information to select the appropriate solvent.
|
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| References |
|
| Molecular Weight |
493.94 |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Formula |
C₂₃H₂₈ClN₃O₇ |
||||||||||||
| CAS No. |
13614-98-7 |
||||||||||||
| Storage |
|
||||||||||||
| Shipping | Room temperature in continental US; may vary elsewhere |
||||||||||||
| Solvent & Solubility |
H2O: 2.45 mg/mL; DMSO: 0.49 mg/mL
* "<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation=""> |
Purity: 99.61%
COA (96 KB) HNMR (283 KB) LCMS (280 KB)
Handling Instructions (1252 KB)-
[1]. Hu X, Wu B, Wang X, et al. Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol. 2011 Mar 11;654(3):274-9.
[2]. Tao R, Kim SH, Honbo N, et al. Minocycline protects cardiac myocytes against simulated ischemia-reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J Cardiovasc Pharmacol. 2010 Dec;56(6):659-68. doi: 10.1097/FJC.0b013e3181faeaf0.
[3]. Padi SS, Kulkarni SK. Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. Eur J Pharmacol. 2008 Dec 28;601(1-3):79-87. doi: 10.1016/j.ejphar.2008.10.018.
[4]. Brundula V, Rewcastle NB, Metz LM, et al. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain. 2002 Jun;125(Pt 6):1297-308.
[5]. Tikka T, Fiebich BL, Goldsteins G, et al. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 2001 Apr 15;21(8):2580-8.
